$PEN — BUY 📊

$PEN — BUY 📊 Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. 🎯 Q1 FY26 | Rev $0B | EPS $1.18 vs $1.11 🟢 💡 Consensus expects moderate growth, but the beat and underlying trends suggest accelerating adoption of Penumbra's products (e.g., RED catheter, stroke thrombectomy systems). The stock's high valuation already prices in high growth, yet the market underappreciates the pipeline and market share gains, creating a gap for upward estimate revisions and... 📉 Reward/Risk: 2.5:1 🏢 Business Quality: 7/10 - Penumbra is a leader in thrombectomy and embolization with a strong innovation track record and high recurring revenue from consumables, but faces intense competition and regulatory risks. 📊 Our read: BUY. Full analysis → https://stockduty.xyz/s/PEN0621

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.